Alleviating solid stress to overcome immunotherapy resistance in metastatic breast cancer

减轻实体应激以克服转移性乳腺癌的免疫治疗耐药性

基本信息

批准号：
9328252
负责人：
Hadi Tavakoli Nia
金额：
$ 6.1万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-01 至 2020-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9328252
关键词：
Achievement Address Adverse effects Affect Angiotensin II Angiotensin II Receptor Angiotensin Receptor Antibodies Atomic Force Microscopy Biology Biomechanics Biomedical Engineering Blood Vessels Brain Breast Cancer Cell Breast Cancer Patient Breast cancer metastasis Cancer Etiology Cancer Model Career Choice Cells Cephalic Cessation of life Chronic Committee Members Cytotoxic T-Lymphocyte-Associated Protein 4 Data Development Disease Disease Progression Dose Drug Design Environment Exposure to Extracellular Matrix Fibroblasts Fibrosis Generations Histologic Hypotension Hypoxia Immune Immune checkpoint inhibitor Immune response Immunology Immunosuppression Immunosuppressive Agents Immunotherapy In Situ Infiltration Internal Breast Prosthesis Malignant Neoplasms Malignant neoplasm of brain Maps Measurement Measures Mechanics Mediating Metastatic Neoplasm to the Lung Metastatic breast cancer Metastatic malignant neoplasm to brain Methods Modality Modeling Modulus Molecular Natural Immunity Neoplasm Metastasis Outcome PDCD1LG1 gene Pathway interactions Patients Perfusion Phenotype Polymers Process Production Research Research Personnel Resistance Resolution Resources Role Signal Transduction Solid Stress Stromal Cells Systemic Therapy Techniques Testing Therapeutic Therapeutic Agents Tissues Toxic effect Training Ultrasonography Work adaptive immunity base blood perfusion cancer cell cancer site cancer therapy career chemotherapy cost cranium cytokine experience experimental study immune checkpoint improved intravital microscopy malignant breast neoplasm mathematical model mechanical force mechanical pressure mortality mouse model multimodality novel novel therapeutics outcome forecast pressure quantum receptor response therapy resistant treatment effect tumor tumor microenvironment valsartan

项目摘要

PROJECT SUMMARY/ABSTRACT Metastatic breast cancer (mBC) is the chief cause of mortality among breast cancer (BC) patients. The dismal outcomes of systemic therapies for this disease are due in part to our incomplete understanding of critical interactions between the mBC cells and their microenvironment, in particular of the role of physical forces in disease progression and treatment resistance. The local microenvironment is known to mediate disease progression and treatment resistance differentially in primary versus metastatic BC. In this proposed project, I will explore how the mechanical microenvironment of metastases affects resistance to immunotherapy for mBC. Our lab has previously shown that solid stress — a newly discovered physical abnormality in tumors, defined as the mechanical pressure accumulated within the solid components of the tumor — is elevated in primary BCs and causes pronounced vascular compression (PNAS 2012, Nat Commun 2013). This vascular compression leads to decreased blood perfusion and increased hypoxia, both of which could promote BC immunosuppression (PNAS 2011 & 2012). We have discovered that the accumulation of solid stress in primary BCs is due to desmoplasia, characterized by high levels of cancer-associated fibroblasts and extracellular matrix components (PNAS 2012). We have also found that primary BC desmoplasia can be reduced using high doses of angiotensin II receptor 1 blockers (ARBs), but at the cost of adverse effects (hypotension) (PNAS 2011). What remains unknown is whether solid stress is elevated in metastases, at what stage it begins to accumulate, and which components or processes mediate its genesis. Also unclear is whether reduction of solid stress results in reprogramming the immune microenvironment, and eventually enhancing immunotherapy in mBC. Here I propose to first quantify solid stress in mBC using novel high-resolution measurement techniques and mathematical modeling. I will then characterize the changes in stromal components and the immune microenvironment in response to solid stress alterations to identify the consequences of solid stress (Aim 1). In Aims 2, based on promising preliminary data, I will utilize newly developed ARB-based therapeutics that selectively become active in the mBC microenvironment to alleviate solid stress. In doing so, I will create therapies that can target solid stress in mBC while avoiding systemic side effects. I will test whether these agents can reduce solid stress, reprogram the immune microenvironment, and enhance the outcomes of immune checkpoint inhibitors in mBC models. The proposed work will lead to new paradigms for the study of mBC and will improve immunotherapy for this intractable disease.

项目摘要/摘要转移性乳腺癌（MBC）是乳腺癌（BC）患者死亡率的主要原因。令人沮丧的结果这种疾病的全身疗法部分是由于我们对批判性相互作用的不完全理解 MBC细胞及其微环境，特别是物理力在疾病进展和治疗中的作用反抗。众所周知，局部微环境在疾病进展和治疗抗药性中的介导不同初级与转移性BC。在这个拟议的项目中，我将探讨如何机械微环境转移会影响MBC免疫疗法的耐药性。我们的实验室以前已经表明了坚固的压力 - 新的发现肿瘤中的身体异常，定义为固体组件中积累的机械压力肿瘤 - 原发性BC中升高，并导致明显的血管压缩（PNAS 2012，NAT Commun 2013）。这种血管压缩导致血液灌注减少和缺氧增加，这两者都可以促进 BC免疫抑制（PNAS 2011和2012）。我们已经发现，固体应力在原发性BC中的积累是由于脱木质质，其特征是高水平与癌症相关的成纤维细胞和细胞外基质成分（PNAS 2012）。我们还发现，使用高剂量的血管紧张素II可以减少原发性bc desmoplasia 受体1个阻滞剂（ARB），但以不良反应为代价（低血压）（PNAS 2011）。仍然未知的是固体应力是否在转移中升高，在哪个阶段开始积累以及哪些组成部分或过程调解其起源。还不清楚的是减少固体应力是否导致重编程免疫微环境，最终增强了MBC的免疫疗法。在这里，我建议首先量化MBC中的固体应力使用新型的高分辨率测量技术和数学建模。然后，我将描述更改基质成分和免疫微环境响应固体应力改变，以鉴定后果坚固的压力（目标1）。在AIMS 2中，基于有希望的初步数据，我将利用新开发的基于ARB的在MBC微环境中有选择地活跃以减轻固体应力的治疗。这样，我会创建可以针对MBC中固体应力的疗法，同时避免全身副作用。我将测试这些代理商是否可以减轻固体应力，重新编程免疫微环境并增强免疫检查点的结果 MBC模型中的抑制剂。拟议的工作将为MBC研究带来新的范式，并将改善这种顽固疾病的免疫疗法。